Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.32 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.32 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763982 | 0.85 | MEN1 (0.35) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL28363935 | 0.83 | MEN1 (0.36) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL28363933 | 0.83 | MEN1 (0.36) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL28884876 | 0.81 | MEN1 (0.37) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL28659211 | 0.81 | HDAC1 (0.42) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL28884875 | 0.81 | MEN1 (0.37) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL16284725 | 0.81 | HDAC1 (0.42) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL20743507 | 0.81 | MEN1 (0.37) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL20743509 | 0.81 | MEN1 (0.37) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL3626322 | 0.80 | CYP1A2 (0.38) | MEN1GAAKMT2ATPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431738-B2 | Optically active α-amino acid into which BSH is introduced and method for synthesizing the same | STELLA PHARMA CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20110124914-A1 | OPTICALLY ACTIVE ALPHA-AMINO ACID INTO WHICH BSH IS INTRODUCED AND METHOD FOR SYNTHESIZING THE SAME | STELLA PHARMA CORPORATION (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2319850-A1 | OPTICALLY ACTIVE -AMINO ACID INTO WHICH BSH IS INTRODUCED AND METHOD FOR SYNTHESIZING THE SAME | Stella Pharma Corporation (JP) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124914-A1 | OPTICALLY ACTIVE ALPHA-AMINO ACID INTO WHICH BSH IS INTRODUCED AND METHOD FOR SYNTHESIZING THE SAME | BCAT1, BCAT2, CTH | MEN1 867/4885GAA 1498/4885KMT2A 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.